Deceased Uterine Transplant in Absolute Uterine Infertility (AUIF)
NCT04026893 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250
Last updated 2026-04-28
Summary
Our study will explore the feasibility of initiating a deceased donor uterine transplant program in addition to the existing living donor IRB at BWH.
Using the template established by teams around the world, we will identify emotionally and socially stable females of reproductive age with intact ovaries who are unable to gestate a child due to congenital or acquired uterine factor infertility. After careful screening, participants will undergo egg harvest, in vitro fertilization, and embryo cryopreservation using standard methods. Women who successfully complete the fertilization of at least six euploid embryos will be eligible to be placed on the waitlist for a deceased donor uterus transplant. After a successful transplant and a period of observation to ensure normal menstrual cycle and graft viability (anticipate six months), embryo implantation will be undertaken.
Following an embryo transfer, gestation will be carefully monitored by our high-risk pregnancy specialists. Medical research interventions include the surgical implantation of a uterus utilizing techniques by teams that have applied this approach successfully, close post-transplant follow up including immunosuppression therapy tailored to established standards during pregnancy minimizing fetal risks, and careful management of pregnancy. After childbearing is complete (at most two gestations), the donor uterus will be removed either during Cesarean or during an elective procedure. In addition, open ended interviews and surveys will be conducted to elicit ethical and psychosocial concerns arising from the experience of subjects and their families, health care providers, and the wider community. The investigator's intent is to monitor outcomes for transplant recipients as well as the live born infants for 30 days after removal of the transplanted uterus.
It is estimated that the time from screening to a potential live birth will be a minimum of 22 months, but likely between 24 - 36 months depending on organ availability.
Conditions
- Infertility of Uterine Origin
Interventions
- PROCEDURE
-
Uterine Transplant from Deceased Donor
The recipient will be started on anti-rejection medications (as is routine for transplant recipients) prior to the OR. Standard of care anesthesia and line placement will take place. The recipient will be appropriately identified as an organ recipient and the donor organ identified per required transplant protocols already in place. The recipient team will then connect the vasculature and appropriate supporting structures for the uterus transplant. Once the organ has been re-perfused, the remainder of the operation will take place and the patient will be moved to the Intensive Care Unit and later to the transplant patient floor for standard monitoring.
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Stefan G Tullius, MD · Brigham and Women's Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 40 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-05-31
- Primary Completion
- 2027-12-31
- Completion
- 2028-01-31
Countries
- United States
Study Locations
More Related Trials
-
Uterine Transplantation for the Treatment of Uterine Factor Infertility
NCT02573415 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
The University of Pennsylvania Uterus Transplant for Uterine Factor Infertility Trial
NCT03307356 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
NCT06261658 ·Status: RECRUITING ·Phase: NA
-
Autologous Ovarian Tissue Transplantation
NCT03496636 ·Status: RECRUITING ·Phase: NA
-
The Combination of Endometrial Injury and Freeze All Strategy in Women With a History of RIF
NCT04597463 ·Status: COMPLETED ·Phase: NA
-
Uterus Transplantation to Treat Infertility
NCT05646992 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Endometrial Local Injury and Implantation Failure
NCT00837733 ·Status: COMPLETED ·Phase: NA
-
Endometrial Biopsy Prior to IVF in Those Patients With Prior Implantation Failure
NCT01800513 ·Status: UNKNOWN ·Phase: NA
-
Apical Pelvic Support in Infertility Patients
NCT04039009 ·Status: UNKNOWN
-
Endometrial Injury In Recurrent Implantation Failure
NCT03748238 ·Status: UNKNOWN ·Phase: NA
-
Efficacy of Uterine Artery Embolization (UAE) in Management of Symptomatic Uterine Adenomyosis
NCT06652945 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Uterus Transplantation From a Multi-organ Donor
NCT03252795 ·Status: RECRUITING ·Phase: NA
-
Feasibility Study of the AblaCare System in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With Infertility Due to Polycystic Ovary Syndrome
NCT05320289 ·Status: COMPLETED ·Phase: NA
-
Endometrial Biopsy in Infertile Patients
NCT00064935 ·Status: COMPLETED ·Phase: PHASE3
-
Predicting Endometrial Receptivity for Optimal Reproductive Management
NCT04107129 ·Status: COMPLETED
-
AD-SVF Therapy for Refractory Endometrial Infertility
NCT07230600 ·Status: RECRUITING ·Phase: PHASE1
-
Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia
NCT04897217 ·Status: WITHDRAWN ·Phase: PHASE3
-
The Effect of Adenomoyosis on Pregnancy Outcomes
NCT04894292 ·Status: UNKNOWN
-
Endometrial Injury for Assisted Reproduction
NCT01132144 ·Status: TERMINATED ·Phase: PHASE3
-
Uterine Artery Embolization and Pelvic Floor Symptoms
NCT00827645 ·Status: WITHDRAWN
-
The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.
NCT01682642 ·Status: COMPLETED ·Phase: PHASE4
-
Adenomyosis and Pregnancy Outcomes in Women Undergoing Assisted Reproductive Technology Treatment
NCT05418140 ·Status: ACTIVE_NOT_RECRUITING
-
Autograft of Human Ovarian Tissue : Efficiency and Safety
NCT02184806 ·Status: UNKNOWN ·Phase: NA
-
anti_endometrial Antibodies in Endometriosis
NCT05851352 ·Status: UNKNOWN
-
The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy
NCT02335203 ·Status: UNKNOWN ·Phase: PHASE2